Insulet Corporation Company Profile (NASDAQ:PODD)

About Insulet Corporation (NASDAQ:PODD)

Insulet Corporation logoInsulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM). The Omnipod System features two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Omnipod System is a discreet two part design, the Omnipod device (Pod) and the PDM that eliminates the need for the external tubing required with conventional pumps. The Pod is a self-adhesive device that the patient fills with insulin and wears directly on the body.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Prosthetics
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:PODD
  • CUSIP: 45784P10
  • Web:
  • Market Cap: $3.33436 billion
  • Outstanding Shares: 58,059,000
Average Prices:
  • 50 Day Moving Avg: $56.08
  • 200 Day Moving Avg: $47.79
  • 52 Week Range: $30.69 - $59.99
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -335.35
  • P/E Growth: -4.57
Sales & Book Value:
  • Annual Revenue: $409.92 million
  • Price / Sales: 8.07
  • Book Value: $1.12 per share
  • Price / Book: 50.90
  • EBIDTA: $9.31 million
  • Net Margins: -7.30%
  • Return on Equity: -46.74%
  • Return on Assets: -6.61%
  • Debt-to-Equity Ratio: 5.27%
  • Current Ratio: 7.06%
  • Quick Ratio: 6.35%
  • Average Volume: 369,975 shs.
  • Beta: 1.51
  • Short Ratio: 11.44

Frequently Asked Questions for Insulet Corporation (NASDAQ:PODD)

What is Insulet Corporation's stock symbol?

Insulet Corporation trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet Corporation's earnings last quarter?

Insulet Corporation (NASDAQ:PODD) posted its earnings results on Thursday, August, 3rd. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.13). The business earned $110 million during the quarter, compared to analyst estimates of $106.23 million. Insulet Corporation had a negative return on equity of 46.74% and a negative net margin of 7.30%. The company's revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.08) earnings per share. View Insulet Corporation's Earnings History.

When will Insulet Corporation make its next earnings announcement?

Insulet Corporation is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Insulet Corporation.

Where is Insulet Corporation's stock going? Where will Insulet Corporation's stock price be in 2017?

15 brokers have issued 12-month price targets for Insulet Corporation's stock. Their forecasts range from $38.00 to $65.00. On average, they anticipate Insulet Corporation's stock price to reach $51.08 in the next twelve months. View Analyst Ratings for Insulet Corporation.

What are analysts saying about Insulet Corporation stock?

Here are some recent quotes from research analysts about Insulet Corporation stock:

  • 1. Northland Securities analysts commented, "Epizyme’s loss per share of $0.48 was less than our estimated $0.66. This resulted from higher than estimated revenue, which was $10 million compared to our estimated $0.6 million, and resulted from a milestone payment. Expenses were in line with expectations. Our outlook for 2017-22 remains basically unchanged. We are adjusting our 2017 estimates to reflect the milestone payment in this quarter." (8/4/2017)
  • 2. According to Zacks Investment Research, "INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. " (7/20/2017)
  • 3. Jefferies Group LLC analysts commented, "PODD's 4Q sales were $3mn above guidance with strength in all areas: US +17%, OUS +35%, and DD +34%. New patient starts in 2016 at +13% missed the +20% annual target reiterated just last Q. To this end, mgmt highlighted that a more important metric to pay attention to is the 15k total patient adds (vs. 13k in 2015) and the installed base grew by 15%. Despite 670G around the corner, Insulet remains largely dismissive of the launch." (2/28/2017)
  • 4. Wedbush analysts commented, " Insulet posted robust 4Q16 results and issued healthy 2017 guidance, signaling confidence in the overall growth of its diabetes and drug delivery franchises despite a more competitive diabetes landscape. PODD's relatively new management continues to fire on all cylinders with betterthan-expected revenues across all three of its business segments and solid gross margin expansion. The main takeaways from the quarter were continued strength within the company's diabetes franchises (US and OUS), the success of its drug delivery segment, and the confidence that momentum should continue in 2017" (2/28/2017)

Who are some of Insulet Corporation's key competitors?

Who are Insulet Corporation's key executives?

Insulet Corporation's management team includes the folowing people:

  • Patrick J. Sullivan, Chairman of the Board, Chief Executive Officer
  • Shacey Petrovic, President, Chief Operating Officer
  • Michael L. Levitz, Chief Financial Officer, Senior Vice President, Treasurer
  • Bradley B. Thomas, Executive Vice President - Human Resources and Organizational Development
  • David Colleran J.D., Senior Vice President, General Counsel, Secretary
  • Aiman Abdel-Malek Ph.D., Senior Vice President - Advanced Technology and Engineering
  • Charles Alpuche, Senior Vice President - Global Manufacturing and Operations
  • Michael Spears, Senior Vice President - Quality and Regulatory Affairs
  • Bret Christensen, Chief Commercial Officer
  • Jessica Hopfield Ph.D., Lead Independent Director

Who owns Insulet Corporation stock?

Insulet Corporation's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Capital Research Global Investors (10.13%), Vanguard Group Inc. (8.04%), BlackRock Inc. (6.90%), Frontier Capital Management Co. LLC (3.12%) and Fred Alger Management Inc. (2.18%). Company insiders that own Insulet Corporation stock include Bradley A Thomas, Charles Alpuche, Daniel J Levangie, David A Lemoine, Jessica Hopfield, Joseph S Zakrzewski, Michael P Spears, Patrick J Sullivan and Regina O Sommer. View Institutional Ownership Trends for Insulet Corporation.

Who sold Insulet Corporation stock? Who is selling Insulet Corporation stock?

Insulet Corporation's stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, BlackRock Inc., Rainier Investment Management LLC, Goldman Sachs Group Inc., UBS Asset Management Americas Inc., JPMorgan Chase & Co., Federated Investors Inc. PA and Fiera Capital Corp. Company insiders that have sold Insulet Corporation stock in the last year include David A Lemoine, Joseph S Zakrzewski and Regina O Sommer. View Insider Buying and Selling for Insulet Corporation.

Who bought Insulet Corporation stock? Who is buying Insulet Corporation stock?

Insulet Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Lord Abbett & CO. LLC, Renaissance Technologies LLC, Marshall Wace North America L.P., Capital Research Global Investors, Vanguard Group Inc., State Street Corp and Delta Lloyd Asset Management N.V.. Company insiders that have bought Insulet Corporation stock in the last two years include Bradley A Thomas, Charles Alpuche, Jessica Hopfield, Michael P Spears and Patrick J Sullivan. View Insider Buying and Selling for Insulet Corporation.

How do I buy Insulet Corporation stock?

Shares of Insulet Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insulet Corporation's stock price today?

One share of Insulet Corporation stock can currently be purchased for approximately $57.01.

MarketBeat Community Rating for Insulet Corporation (NASDAQ PODD)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  386 (Vote Outperform)
Underperform Votes:  338 (Vote Underperform)
Total Votes:  724
MarketBeat's community ratings are surveys of what our community members think about Insulet Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Insulet Corporation (NASDAQ:PODD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $51.08 (10.41% downside)

Analysts' Ratings History for Insulet Corporation (NASDAQ:PODD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/15/2017Barclays PLCInitiated CoverageOverweight -> Overweight$65.00LowView Rating Details
8/9/2017Jefferies Group LLCReiterated RatingBuy$48.00 -> $58.00LowView Rating Details
8/4/2017Oppenheimer Holdings, Inc.Set Price TargetHold$55.00LowView Rating Details
8/4/2017Northland SecuritiesReiterated RatingBuyLowView Rating Details
8/4/2017Cowen and CompanyReiterated RatingOutperform$52.00 -> $63.00HighView Rating Details
7/17/2017BTIG ResearchDowngradeBuy -> NeutralMediumView Rating Details
7/11/2017Canaccord GenuityReiterated RatingHold$42.00 -> $50.00LowView Rating Details
5/25/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
5/22/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$47.00LowView Rating Details
5/14/2017B. RileyReiterated RatingNeutral$44.00LowView Rating Details
2/28/2017WedbushBoost Price TargetOutperform -> Outperform$48.00 -> $50.00N/AView Rating Details
2/27/2017Feltl & Co.DowngradeBuy -> HoldN/AView Rating Details
1/6/2017Robert W. BairdUpgradeNeutral -> Outperform$39.00 -> $47.00N/AView Rating Details
11/17/2016J P Morgan Chase & CoReiterated RatingHold$38.00N/AView Rating Details
11/7/2016Leerink SwannReiterated RatingOutperform$55.00 -> $50.00N/AView Rating Details
5/16/2016Sterne Agee CRTReiterated RatingNeutralN/AView Rating Details
2/26/2016Benchmark Co.UpgradeHold -> Buy$30.00 -> $40.00N/AView Rating Details
11/2/2015Morgan StanleyInitiated CoverageEqual -> Equal Weight$32.00N/AView Rating Details
(Data available from 9/26/2015 forward)


Earnings History for Insulet Corporation (NASDAQ:PODD)
Earnings by Quarter for Insulet Corporation (NASDAQ:PODD)
Earnings History by Quarter for Insulet Corporation (NASDAQ PODD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.13)($0.13)$106.23 million$110.00 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.16)($0.17)$97.73 million$101.70 millionViewListenView Earnings Details
2/27/2017Q416($0.05)($0.16)$100.61 million$103.58 millionViewListenView Earnings Details
11/3/2016Q316($0.09)($0.05)$89.75 million$94.90 millionViewN/AView Earnings Details
8/3/2016Q216($0.17)($0.08)$81.10 million$87.30 millionViewN/AView Earnings Details
4/28/2016Q116($0.19)($0.19)$79.06 million$81.21 millionViewListenView Earnings Details
2/25/2016Q415($0.26)($0.48)$91.89 million$100.10 millionViewListenView Earnings Details
11/5/2015Q315($0.26)($0.33)$83.56 million$87.30 millionViewListenView Earnings Details
8/12/2015Q215($0.13)($0.27)$70.32 million$75.60 millionViewListenView Earnings Details
4/30/2015Q115($0.10)($0.21)$68.20 million$61.20 millionViewN/AView Earnings Details
2/26/2015Q414($0.04)($0.10)$73.52 million$72.60 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.06)$72.94 million$72.00 millionViewN/AView Earnings Details
5/7/2014Q114($0.06)($0.11)$68.47 million$69.20 millionViewN/AView Earnings Details
2/27/2014Q413($0.09)($0.04)$67.94 million$68.53 millionViewN/AView Earnings Details
11/7/2013Q313($0.16)($0.39)$62.01 million$61.10 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.20)$60.47 million$60.09 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.21)($0.20)$57.26 million$57.40 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.21)($0.21)$59.12 million$57.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.26)$54.93 million$54.80 millionViewN/AView Earnings Details
8/8/2012($0.25)($0.30)ViewN/AView Earnings Details
5/9/2012($0.28)($0.31)ViewN/AView Earnings Details
2/9/2012($0.26)($0.30)ViewN/AView Earnings Details
11/3/2011($0.25)($0.29)ViewN/AView Earnings Details
8/2/2011($0.21)($0.42)ViewN/AView Earnings Details
5/9/2011($0.22)($0.22)ViewN/AView Earnings Details
2/15/2011($0.26)($0.50)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Insulet Corporation (NASDAQ:PODD)
2017 EPS Consensus Estimate: ($0.46)
2018 EPS Consensus Estimate: ($0.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20178($0.23)($0.10)($0.15)
Q2 20178($0.16)($0.04)($0.12)
Q3 20178($0.13)($0.02)($0.09)
Q4 20178($0.11)($0.02)($0.09)
Q1 20185($0.11)$0.02($0.06)
Q2 20185($0.11)$0.05($0.02)
Q3 20184($0.10)$0.06$0.00
Q4 20184($0.09)$0.06($0.01)
(Data provided by Zacks Investment Research)


Dividend History for Insulet Corporation (NASDAQ:PODD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Insulet Corporation (NASDAQ:PODD)
Insider Ownership Percentage: 2.60%
Insider Trades by Quarter for Insulet Corporation (NASDAQ:PODD)
Institutional Ownership by Quarter for Insulet Corporation (NASDAQ:PODD)
Insider Trades by Quarter for Insulet Corporation (NASDAQ:PODD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/6/2017Charles AlpucheEVPBuy2,500$58.08$145,200.00View SEC Filing  
5/16/2017Michael P. SpearsSVPBuy2,500$40.59$101,475.00View SEC Filing  
5/11/2017Bradley A. ThomasEVPBuy3,000$38.69$116,070.00View SEC Filing  
5/11/2017Jessica HopfieldDirectorBuy2,580$38.68$99,794.40View SEC Filing  
5/1/2017David A. LemoineDirectorSell1,524$43.40$66,141.60View SEC Filing  
3/13/2017Regina O. SommerDirectorSell40,000$45.00$1,800,000.00View SEC Filing  
3/6/2017David A. LemoineDirectorSell1,282$45.15$57,882.30View SEC Filing  
3/2/2017Joseph S. ZakrzewskiDirectorSell40,000$46.86$1,874,400.00View SEC Filing  
12/9/2016Charles AlpucheSVPBuy6,600$37.70$248,820.00View SEC Filing  
12/2/2016Patrick J. SullivanCEOBuy40,000$33.89$1,355,600.00View SEC Filing  
12/1/2016Bradley A. ThomasEVPBuy3,100$32.45$100,595.00View SEC Filing  
5/25/2016Regina O SommerDirectorSell8,019$30.42$243,937.98View SEC Filing  
5/18/2016Patrick J SullivanCEOBuy45,000$27.00$1,215,000.00View SEC Filing  
5/13/2016Bradley A ThomasEVPBuy2,975$26.63$79,224.25View SEC Filing  
5/5/2016Bradley A ThomasEVPBuy1,656$30.13$49,895.28View SEC Filing  
3/10/2016Daniel J LevangieInsiderSell12,299$30.89$379,916.11View SEC Filing  
3/7/2016Daniel J LevangieInsiderSell7,663$31.15$238,702.45View SEC Filing  
3/2/2016Jessica HopfieldDirectorBuy3,230$30.91$99,839.30View SEC Filing  
6/5/2015Patrick J SullivanCEOBuy10,000$29.39$293,900.00View SEC Filing  
5/28/2015Patrick J SullivanCEOBuy20,000$27.91$558,200.00View SEC Filing  
5/15/2015Timothy J ScannellDirectorBuy3,500$27.05$94,675.00View SEC Filing  
5/5/2015Bradley A ThomasEVPBuy1,000$27.26$27,260.00View SEC Filing  
5/5/2015Patrick RyanCOOBuy3,669$26.99$99,026.31View SEC Filing  
4/2/2015R Anthony DiehlGeneral CounselSell3,372$30.96$104,397.12View SEC Filing  
3/9/2015Patrick J SullivanCEOBuy10,000$31.93$319,300.00View SEC Filing  
3/2/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
2/12/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
1/2/2015Charles T LiamosDirectorSell4,000$46.08$184,320.00View SEC Filing  
11/3/2014Charles T LiamosDirectorSell4,000$42.95$171,800.00View SEC Filing  
10/1/2014Charles T LiamosDirectorSell4,000$36.58$146,320.00View SEC Filing  
10/1/2014R Anthony DiehlGeneral CounselSell1,250$36.59$45,737.50View SEC Filing  
9/10/2014Charles T LiamosDirectorSell4,000$35.17$140,680.00View SEC Filing  
9/2/2014Duane DesistoCEOSell20,000$36.30$726,000.00View SEC Filing  
8/1/2014Duane DesistoCEOSell20,000$34.23$684,600.00View SEC Filing  
7/1/2014Duane DesistoCEOSell20,000$40.52$810,400.00View SEC Filing  
7/1/2014R Anthony DiehlGeneral CounselSell1,250$39.65$49,562.50View SEC Filing  
6/11/2014R Anthony DiehlGeneral CounselSell17,871$37.09$662,835.39View SEC Filing  
6/9/2014Peter DevlinInsiderSell12,314$37.10$456,849.40View SEC Filing  
4/8/2014Peter DevlinInsiderSell30,000$41.25$1,237,500.00View SEC Filing  
4/3/2014R Anthony DiehlGeneral CounselSell4,617$48.67$224,709.39View SEC Filing  
3/6/2014R Anthony DiehlGeneral CounselSell12,458$49.28$613,930.24View SEC Filing  
3/6/2014Tracey Haas WielinskiVPSell8,275$49.21$407,212.75View SEC Filing  
2/3/2014Charles LiamosDirectorSell11,037$42.93$473,818.41View SEC Filing  
2/3/2014Duane DesistoCEOSell20,000$42.95$859,000.00View SEC Filing  
2/3/2014Peter DevlinInsiderSell30,000$42.82$1,284,600.00View SEC Filing  
1/3/2014Charles LiamosCOOSell86,000$36.02$3,097,720.00View SEC Filing  
1/2/2014Duane DesistoCEOSell20,000$36.07$721,400.00View SEC Filing  
12/3/2013Charles LiamosCOOSell63,808$36.26$2,313,678.08View SEC Filing  
11/18/2013Charles LiamosCOOSell80,000$35.60$2,848,000.00View SEC Filing  
9/3/2013Duane DesistoCEOSell20,000$33.38$667,600.00View SEC Filing  
8/29/2013Sally CrawfordDirectorSell9,000$33.42$300,780.00View SEC Filing  
8/15/2013Regina SommerDirectorSell5,000$33.32$166,600.00View SEC Filing  
8/1/2013Duane DesistoCEOSell20,000$31.85$637,000.00View SEC Filing  
7/1/2013Duane DesistoCEOSell20,000$31.51$630,200.00View SEC Filing  
7/1/2013Peter DevlinInsiderSell30,000$31.48$944,400.00View SEC Filing  
6/14/2013Sally CrawfordDirectorSell31,000$30.47$944,570.00View SEC Filing  
6/10/2013R Anthony DiehlGeneral CounselSell38,455$30.50$1,172,877.50View SEC Filing  
6/3/2013Duane DesistoCEOSell20,000$29.76$595,200.00View SEC Filing  
12/3/2012Brian K RobertsCFOSell10,000$21.92$219,200.00View SEC Filing  
11/1/2012Brian K RobertsCFOSell10,000$21.49$214,900.00View SEC Filing  
9/4/2012Brian K RobertsCFOSell10,000$20.78$207,800.00View SEC Filing  
9/4/2012Duane DesistoCEOSell20,000$20.97$419,400.00View SEC Filing  
9/4/2012Ruthann DepietroVPSell1,000$20.90$20,900.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Insulet Corporation (NASDAQ:PODD)
Latest Headlines for Insulet Corporation (NASDAQ:PODD)
DateHeadline logoInsulet Corporation (PODD) Receives Average Recommendation of "Buy" from Analysts - September 17 at 12:52 AM logoBarclays PLC Begins Coverage on Insulet Corporation (PODD) - September 16 at 12:26 AM logoInsulet Corporation Presents Real-World Clinical Data on the Use of Its Omnipod® Insulin Management System in Approximately 39,000 Patients Using a Cloud-Based Data Management System - September 13 at 7:56 AM logoDaily Technical Summary Reports on Medical Supplies Stocks -- Insulet, Microbot Medical, C.R. Bard, and Hill Rom - September 8 at 7:14 AM logoInsulet Corporation (PODD) Presents At Baird's 2017 Global Healthcare Conference - Slideshow - September 8 at 7:14 AM logoCharles Alpuche Acquires 2,500 Shares of Insulet Corporation (PODD) Stock - September 7 at 8:10 PM logo$114.24 Million in Sales Expected for Insulet Corporation (PODD) This Quarter - September 4 at 8:46 AM logo Analysts Anticipate Insulet Corporation (PODD) to Post -$0.11 Earnings Per Share - September 2 at 6:06 AM logoInsulet Corporation (PODD) Lifted to "Strong-Buy" at BidaskClub - August 25 at 5:56 PM logoInsulet Corporation (PODD) Receives Consensus Rating of "Buy" from Brokerages - August 23 at 12:30 AM logoInsulet Corporation (PODD) Expected to Announce Quarterly Sales of $114.24 Million - August 16 at 1:48 AM logoSee what the IHS Markit Score report has to say about Insulet Corp. - August 13 at 8:11 PM logoInsulet (PODD) Appoints Michael Minogue and James Mullen to Board of Directors - August 11 at 7:42 AM logoInsulet Corporation Appoints Michael R. Minogue and James C. Mullen to Board of Directors - August 11 at 7:42 AM logoInsulet Corporation's (NASDAQ:PODD) "Buy" Rating Reaffirmed at Jefferies Group LLC - August 9 at 12:18 PM logoInsulet Reaches Analyst Target Price - August 8 at 6:19 AM logoQ2 2018 Earnings Forecast for Insulet Corporation (NASDAQ:PODD) Issued By Northcoast Research - August 7 at 8:22 AM logoEquities Analysts Offer Predictions for Insulet Corporation's Q1 2018 Earnings (PODD) - August 7 at 8:02 AM logoInsulet Corporation (NASDAQ:PODD) Rating Reiterated by Cowen and Company - August 6 at 9:40 PM logoInsulet Corporation (PODD) PT Set at $55.00 by Oppenheimer Holdings, Inc. - August 6 at 6:28 PM logoInsulet Corporation (NASDAQ:PODD) Posts Quarterly Earnings Results, Meets Expectations - August 5 at 12:56 PM logoInsulet Delivers 26% Revenue Growth and Raises 2017 Guidance; Stock Pumps Up 7% - August 5 at 10:35 AM logoInsulet Corporation (PODD) PT Raised to $63 at Cowen on 2Q Report; 'Direct Europe Commercialization Drives Sharp Upward Estimate Revisions' - August 5 at 6:20 AM logoInsulet Corporation (NASDAQ:PODD) Receives "Buy" Rating from Northland Securities - August 4 at 11:50 AM logoComparing Insulet Corporation (NASDAQ:PODD) and Delcath Systems (DCTH) - August 4 at 8:26 AM logoInsulet Reports Second Quarter 2017 Financial Results - August 4 at 7:08 AM logoInsulet reports 2Q loss - August 4 at 7:08 AM logoEdited Transcript of PODD earnings conference call or presentation 3-Aug-17 8:30pm GMT - August 4 at 7:08 AM logoInsulet’s Programs at the American Association of Diabetes Educators Conference and Its New San Diego Innovation Center of Excellence Highlight Company’s Commitment to Innovation - August 3 at 7:02 AM logoInsulet Corporation (NASDAQ:PODD) vs. ReWalk Robotics (RWLK) Head-To-Head Review - August 1 at 9:23 AM logoZacks: Brokerages Expect Insulet Corporation (PODD) Will Post Quarterly Sales of $106.05 Million - July 29 at 7:45 AM logoInsulet Corporation (PODD) Given Average Rating of "Buy" by Brokerages - July 29 at 12:43 AM logoInsulet Corporation (NASDAQ:PODD) Scheduled to Post Earnings on Thursday - July 27 at 3:01 PM logo-$0.13 EPS Expected for Insulet Corporation (NASDAQ:PODD) This Quarter - July 27 at 2:26 PM logoInteresting PODD Put And Call Options For August 18th - July 26 at 6:28 AM logoFinancial Contrast: Insulet Corporation (NASDAQ:PODD) & ReWalk Robotics (RWLK) - July 24 at 9:24 AM logoInsulet Corporation (NASDAQ:PODD) Rating Reiterated by Oppenheimer Holdings, Inc. - July 23 at 9:26 PM logoUpdates To Insulet Thesis: Innovation And Growth Continue - July 23 at 7:10 AM logoForm 8-K INSULET CORP For: Jul 20 - July 21 at 6:19 AM logoForm 8-K INSULET CORP For: Jul 20 - July 21 at 6:19 AM logoInsulet to Assume Distribution and Commercial Support for Its Omnipod ® System in Europe - July 21 at 6:19 AM logoInsulet to Assume Distribution and Commercial Support for Its Omnipod ® System in Europe - July 21 at 6:19 AM logoInsulet to Assume Distribution and Commercial Support for Its Omnipod® System in Europe - July 21 at 6:19 AM logoInsulet to Assume Distribution and Commercial Support for Its Omnipod® System in Europe - July 21 at 6:19 AM logoInsulet Corporation (NASDAQ:PODD) Lowered to Hold at Zacks Investment Research - July 20 at 11:26 PM logoAnalyzing Insulet Corporation (NASDAQ:PODD) & Delcath Systems (DCTH) - July 19 at 8:53 AM logoInsulet Downgraded Despite Expectations For Strong Performance - July 18 at 7:26 AM logoInsulet Corporation (NASDAQ:PODD) & Delcath Systems (DCTH) Head to Head Comparison - July 17 at 10:27 AM logoInsulet Corporation (NASDAQ:PODD) Lowered to Neutral at BTIG Research - July 17 at 9:58 AM logoInsulet Corporation (PODD) Earns "Buy" Rating from Jefferies Group LLC - July 15 at 3:35 PM



Insulet Corporation (PODD) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by Staff